By: Carrie A. Shults

INTRODUCTION

Outsourcing to Contract Development and Manufacturing Organizations (CDMOs) has become a common practice across pharmaceutical and biotechnology companies as pipelines expand, timelines compress, and internal resources remain constrained. Selecting the right partner directly influences development speed, program cost, technical risk, and the likelihood of a successful transition from development to clinical manufacturing.

For lyophilized sterile injectables, the stakes are even higher. Freeze-dried products present unique formulation, processing, analytical, and manufacturing challenges that require specialized expertise. This guide outlines practical considerations for selecting and managing CDMO partnerships from early development through clinical trial material (CTM) manufacturing and beyond, with an emphasis on technical capability, governance, and risk management rather than marketing claims.

STRATEGIC VS. TACTICAL PARTNERSHIPS: CHOOSING THE RIGHT MODEL

Organizations typically engage CDMOs using one of two approaches. A strategic partnership involves a long-term relationship in which a single provider supports multiple functions across development and manufacturing. This model works well when portfolio continuity, knowledge retention, and integrated execution are priorities.

A tactical partnership focuses on a defined scope of work, such as formulation development, lyophilization process design, analytical testing, or clinical manufacturing. This approach can provide access to highly specialized expertise without committing an entire program to a single provider.

Neither model is inherently superior. The appropriate choice depends on program objectives, available internal expertise, risk tolerance, and development timelines. Many organizations successfully combine both approaches by maintaining strategic relationships for core activities while engaging technical specialists for specific challenges.

MAPPING THE CRITICAL PATH

The major development milestones for most injectable products are similar, but lyophilized products require greater attention to interactions among activities that are often managed independently. Critical development areas include:

• API and/or DS manufacturing and characterization
• Analytical method development and qualification
• Product design and presentation selection
• Formulation development
• Lyophilization feasibility and process development
• Aseptic process engineering
• Clinical manufacturing and technology transfer planning

Few organizations excel equally across all disciplines. Effective project management depends on assembling the right expertise at the right time while ensuring decisions in one area support downstream manufacturing and regulatory objectives. Importantly, development activities should never be viewed in isolation. Early formulation and process development decisions can significantly influence manufacturing success, scalability, product robustness, and future technology transfer efforts.

WHY LYOPHILIZATION REQUIRES SPECIALIZED EXPERTISE

Sterility & Aseptic Operations:
Lyophilized drug products are typically sterile injections. Successful programs require integration of aseptic processing principles with lyophilization process development from the earliest stages.

Container-Closure Considerations:
Vial geometry, stopper design, venting characteristics, and seal integrity can affect moisture content, reconstitution time, sterility assurance, and long-term stability.

Critical Quality Attributes (CQAs):
Residual moisture, reconstitution time, potency retention, and particulate burden are especially sensitive to formulation and processing conditions.

Regulatory Complexity:
Although global harmonization efforts continue, many regulatory expectations were initially developed around liquid products. Consequently, lyophilized products often require greater scientific justification and documented rationale throughout development.

Many organizations own lyophilization equipment; far fewer possess the scientific foundation and process engineering and manufacturing expertise required to consistently design robust processes which scale and transfer successfully between facilities. As outsourced options continue to expand, sponsors should evaluate demonstrated technical experience and performance rather than relying solely on equipment lists or facility size.

It is also important to recognize that many CDMOs transfer products and processes from a development laboratory to a clinical manufacturing setting, and ultimately to commercial scale manufacturing facility. In some cases, this may be different buildings on a single site, or entirely different sites, and even different countries.

WHAT GOOD LOOKS LIKE IN A LYOPHILIZATION CDMO

When evaluating potential partners, focus on evidence of technical capability and operational execution.

Flexibility with Control:
Phase I and Phase II programs often operate under evolving timelines, limited API or Drug Substance availability, and changing clinical requirements. Strong CDMOs adapt development plans, batch sizes, and study designs while maintaining GMP compliance, data integrity, and disciplined change management. They openly discuss development tradeoffs rather than forcing programs into predefined service packages.

Scientific Depth Beyond Equipment:
Technical expertise should extend well beyond access to manufacturing assets. Effective providers begin with the Target Product Profile (TPP) and consider route of administration, formulation constraints, stability requirements, and future commercial goals when developing product and process strategies. Similar to transferring a process from development into a manufacturing operation, the success of transforming the early TPP to Critical Quality Attributes (CQA is dependent on a level of experience and expertise.

Sponsors should seek evidence that formulation development, process engineering, analytical development, and manufacturing activities are aligned within a common development framework. This integration helps avoid costly redesigns later in development and improves technology transfer success.

Integrated Capabilities:
Sponsors do not necessarily need a provider that performs every function internally. However, they should ensure the CDMO can effectively support the activities most critical to program success based upon their strengths and expertise. For lyophilized products, those capabilities typically include:

• Formulation development
• Product characterization
• Lyophilization process design
• Sterile product clinical manufacturing
• Technology transfer planning
• Analytical support

Cross-functional collaboration among scientists, engineers, quality professionals, and manufacturing personnel is often a stronger predictor of success than the breadth of a provider’s service portfolio.

Communication & Governance:
Technical expertise alone cannot overcome poor project execution. Successful partnerships establish routine communication, clearly defined responsibilities, structured decision-making processes, and proactive change management. Regular working meetings and periodic strategic reviews help teams address issues before they become critical delays.

A PRACTICAL APPROACH TO CDMO SELECTION AND ONBOARDING

Step 1: Translate the TPP into Scientific & Technical Requirements

Define the product needs such as intended use, dosage form, presentation, storage requirements, shelf-life expectations, and reconstitution requirements. These elements should drive development strategy and CDMO selection.

Step 2: Build an Evidence-Based RFP

Avoid generic capability and commercial aspect checklists. Instead, ask potential partners to describe their development philosophy, approach to process design, quality systems, and technology transfer practices. Request examples of how they assess risk, manage limited API or Drug Substance supplies, establish development priorities, and make critical decisions. The goal is to evaluate scientific rigor, problem-solving capability, and operational maturity without requiring disclosure of confidential client programs.

Step 3: Evaluate API-Constrained Development Strategies

Many early-stage programs operate with limited API or Drug Substance supplies. Assess how prospective partners conserve material during formulation studies, process development, engineering runs, and GMP manufacturing. Small-scale modeling approaches can be valuable when supported by sound scientific justification.

Step 4: Review Quality Systems Through a Lyophilization Lens

Standard GMP assessments remain essential, but sponsors should also evaluate how quality systems address lyophilization-specific risks. This encompasses a level of control to achieve process reproducibility, product consistency, and batch uniformity.

Examples include:

• Complete sublimation without collapse or melt-back
• Moisture variability
• Visual cake defects
• Vial-to-vial variability

A strong quality organization understands how these risks relate to both process performance and patient safety.

Step 5: Confirm Analytical Readiness

Analytical methods frequently become hidden critical activities. Ensure methods adequately support product characterization, stability assessments, release testing, and process understanding. Assays should be phase-appropriate while remaining capable of supporting future development needs.

When testing is outsourced, confirm the CDMO has established relationships with qualified laboratories and robust procedures for sample management, method transfer, and data review.

Step 6: Establish Governance Early

Define escalation pathways, decision rights, communication expectations, and change control processes before project execution begins.

Strong governance helps teams respond quickly when technical or operational issues arise.

DESIGNING FOR SCALE & TECHNOLOGY TRANSFER FROM DAY ONE

One of the most common and costly mistakes in lyophilized product development is treating transferability as a later-stage activity. In practice, many manufacturing challenges can be traced back to early development decisions that inadvertently limited process robustness or scalability. The goal in developing a product and engineering a process to be safe, effective, and sufficiently robust is an essential focus in even early planning. The most effective partners build transferability into development activities from the outset.

Build Process Robustness:
Avoid processes that operate at the edge of acceptable performance. Design processes with sufficient operating ranges to accommodate normal variability among facilities, equipment, and material lots.

Make Scalable Component Decisions:
Container-closure systems selected during development should be commercially available and scalable to larger manufacturing volumes. Potential differences in stopper performance, vial geometry, or component sourcing should be assessed early. Recognize that the primary packaging has a significant influence on product quality outcomes.

Standardized Data Collection:
Consistent collection of Critical Process Parameters (CPP) of shelf temperature, chamber pressure and time, and key resulting parameters of product temperature and process performance data improves comparability across development, clinical manufacturing, and eventual commercial operations.

When transferability becomes a development objective rather than an afterthought, technology transfer becomes substantially less complex and less risky.

CLINICAL TRIAL MATERIAL PLANNING & RISK MANAGEMENT

Early clinical manufacturing programs must balance speed, learning, flexibility, quality, and cost. A practical approach begins with scheduling activities based on clinical timelines and API or Drug Substance availability. Programs should be back-planned from key milestones such as first-patient-in dates, enrollment schedules, distribution channels, and stability requirements.

Risk management is equally important:

Technical Risks: Common lyophilization risks include:

• Product collapse
• Melt-back
• Excess residual moisture
• Slow reconstitution
• Product heterogeneity
• Moisture-driven degradation

Mitigation strategies may include feasibility studies, design-of-experiments (DoE) approaches, process characterization, establishing a Proven acceptable range (PAR), and clearly defined acceptance criteria.

Operational Risks:
Potential operational challenges include:

• Process excursions
• Equipment downtime
• Material shortages
• Scheduling conflicts
• Resource constraints

Integrated project schedules, contingency planning, and secondary suppliers for critical materials can help reduce risk exposure.

Regulatory Risks:
Development programs should maintain clear scientific justifications for formulation and process decisions, particularly when existing regulatory guidance does not directly address product-specific circumstances. Contemporaneous documentation is essential from the outset. It simplifies future submissions and supports comparability assessments when development changes occur.

COLLABORATION PRACTICES THAT KEEP PROGRAMS MOVING

The mechanics of collaboration often determine how efficiently technical challenges are resolved. Successful partnerships are characterized by:

• Transparency regarding risks and challenges
• Clearly defined responsibilities
• Formal change management processes
• Routine communication
• Shared commitment to problem solving

Weekly working sessions combined with periodic strategic reviews help maintain alignment while allowing teams to quickly address emerging technical, operational, and regulatory issues.

COMMON PITFALLS AND HOW TO AVOID THEM

Confusing Equipment with Expertise:
Owning a lyophilizer does not guarantee competence in formulation science, process development, aseptic manufacturing, or technology transfer. Success of Lyophilization depends on scientific depth, process understanding, and execution discipline, not simply the presence of hardware.

Evaluate experience, scientific capabilities, and demonstrated outcomes in addition to equipment inventories.

Designing Processes Without Transferability:
Development processes optimized exclusively for a specific laboratory system may become difficult to reproduce elsewhere. Build robustness and transfer considerations into process design from the beginning.

Delaying Container-Closure Decisions:
Vials and stoppers can influence residual moisture, product appearance, process performance, and reconstitution behavior. Establish and verify container-closure strategies as early as practical.

Overlooking Governance:
Unclear responsibilities and poorly defined decision-making processes can slow even technically successful programs. Governance expectations should be documented in project agreements and operational plans before work begins.

BRINGING IT ALL TOGETHER

For lyophilized sterile injectables, successful progression from development through clinical manufacturing depends on selecting partners with the right combination of scientific expertise, manufacturing capability, and project leadership.

While flexibility, quality systems, and communication remain essential, the strongest predictor of long-term success is often a partner’s ability to translate development knowledge into scalable, transferable manufacturing processes. Sponsors should prioritize organizations that integrate formulation science, process engineering, analytical strategy, and manufacturing execution within a cohesive technical framework.

Organizations that emphasize technical depth, proactive risk management, and development-to-manufacturing continuity are better positioned to reduce timelines, control costs, and generate reliable clinical trial materials that support future commercialization.

By selecting the partnership model that best aligns with program objectives, insisting on demonstrated lyophilization expertise, and maintaining disciplined governance throughout execution, sponsors can improve the probability of delivering high-quality clinical materials on time and with confidence in the path forward.

REFERENCES

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q8(R2): Pharmaceutical Development. International Council for Harmonisation; 2009.
2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q9(R1): Quality Risk Management. International Council for Harmonisation; 2023.
3. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q10: Pharmaceutical Quality System. International Council for Harmonisation; 2008.
4. US Food and Drug Administration. Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice. Guidance for Industry. US Department of Health and Human Services, Food and Drug Administration; 2004. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice
5. US Food and Drug Administration. Guide to Inspections of Lyophilization of Parenterals. US Department of Health and Human Services, Food and Drug Administration; July 1993. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/lyophilization-parenteral-793
6. Williams NA, Polli GP. The lyophilization of pharmaceuticals: a literature review. PDA J Pharm Sci Technol. 1984;38(2):48-60.

BIOGRAPHY